Please assess the completion status of the following clinical trial:

Trial Title: Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, medically stable, able to give informed consent, and comply with the protocol.~* Obesity with BMI \>30 kg/m2.~* DM2 for less than 10 years.~* 7.5% \< HA1C \< 10%~* Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)~Exclusion Criteria:~* Mental states that would preclude complete understanding of the protocol and compliance.~* Chronic illness such as renal failure (with creatinine clearance \<80 ml/min for Specific Aim 2).~* Women of child-bearing age because of the potential hazard to the fetus (doxycycline may cause permanent discoloration of the teeth and deposition in bone inhibiting growth) and because doxycycline may render oral contraceptives less effective.~* Nursing mothers.~* Allergy to tetracyclines.~* Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant therapy, antacids containing aluminum, calcium, or magnesium, iron-containing preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or methoxyflurane, thiazolidinediones (TZD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Participants with DM2 receiving doxycycline 100mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Pills prepared identical to doxycycline.

Based on this trial design, predict the completion outcome and termination type (if applicable).